Swiss National Bank Raises Stock Position in FibroGen Inc (NASDAQ:FGEN)

Share on StockTwits

Swiss National Bank increased its stake in FibroGen Inc (NASDAQ:FGEN) by 2.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 143,300 shares of the biopharmaceutical company’s stock after purchasing an additional 3,900 shares during the quarter. Swiss National Bank owned 0.17% of FibroGen worth $6,474,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. FMR LLC raised its position in shares of FibroGen by 2.8% during the 1st quarter. FMR LLC now owns 10,029,786 shares of the biopharmaceutical company’s stock valued at $545,118,000 after purchasing an additional 269,570 shares during the period. Janus Henderson Group PLC raised its position in shares of FibroGen by 13.2% during the 2nd quarter. Janus Henderson Group PLC now owns 2,500,567 shares of the biopharmaceutical company’s stock valued at $112,976,000 after purchasing an additional 291,808 shares during the period. First Trust Advisors LP raised its position in shares of FibroGen by 7.7% during the 2nd quarter. First Trust Advisors LP now owns 2,046,192 shares of the biopharmaceutical company’s stock valued at $92,447,000 after purchasing an additional 145,732 shares during the period. JPMorgan Chase & Co. raised its position in shares of FibroGen by 2.9% during the 1st quarter. JPMorgan Chase & Co. now owns 1,232,560 shares of the biopharmaceutical company’s stock valued at $66,989,000 after purchasing an additional 34,557 shares during the period. Finally, Eagle Asset Management Inc. raised its position in shares of FibroGen by 0.3% during the 1st quarter. Eagle Asset Management Inc. now owns 947,195 shares of the biopharmaceutical company’s stock valued at $51,480,000 after purchasing an additional 2,509 shares during the period. Institutional investors own 64.60% of the company’s stock.

Several analysts have recently commented on FGEN shares. TheStreet upgraded shares of FibroGen from a “d+” rating to a “c” rating in a research report on Tuesday, August 13th. Mizuho reiterated a “buy” rating and issued a $65.00 price target on shares of FibroGen in a report on Monday. ValuEngine downgraded shares of FibroGen from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Piper Jaffray Companies reiterated a “positive” rating and issued a $40.00 price target (down from $65.00) on shares of FibroGen in a report on Monday, May 27th. Finally, Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a report on Tuesday, August 13th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $61.00.

FibroGen stock opened at $43.85 on Wednesday. FibroGen Inc has a twelve month low of $33.51 and a twelve month high of $61.95. The company has a quick ratio of 9.71, a current ratio of 9.73 and a debt-to-equity ratio of 0.07. The company’s 50-day moving average price is $45.69 and its 200-day moving average price is $47.39. The company has a market cap of $3.63 billion, a PE ratio of -42.57 and a beta of 1.86.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $1.75. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The firm had revenue of $191.57 million during the quarter, compared to analysts’ expectations of $29.03 million. During the same period in the previous year, the company earned ($0.28) EPS. The firm’s revenue for the quarter was up 335.9% compared to the same quarter last year. As a group, sell-side analysts expect that FibroGen Inc will post -0.37 earnings per share for the current fiscal year.

In other FibroGen news, SVP Christine Chung sold 11,250 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $43.17, for a total value of $485,662.50. Following the completion of the sale, the senior vice president now directly owns 157,195 shares of the company’s stock, valued at approximately $6,786,108.15. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total transaction of $1,757,063.88. Following the completion of the sale, the chief executive officer now directly owns 2,356,578 shares of the company’s stock, valued at $104,467,102.74. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 277,824 shares of company stock valued at $12,147,057. 7.83% of the stock is owned by corporate insiders.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: Economic Reports

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Regent Investment Management LLC Has $1.81 Million Holdings in Honeywell International Inc.
Regent Investment Management LLC Has $1.81 Million Holdings in Honeywell International Inc.
Regent Investment Management LLC Sells 715 Shares of Kimberly Clark Corp
Regent Investment Management LLC Sells 715 Shares of Kimberly Clark Corp
Mondelez International Inc  Shares Sold by Regent Investment Management LLC
Mondelez International Inc Shares Sold by Regent Investment Management LLC
Occidental Asset Management LLC Has $1.02 Million Holdings in SPDR Nuveen Barclays Short Term Municipal Bond ETF
Occidental Asset Management LLC Has $1.02 Million Holdings in SPDR Nuveen Barclays Short Term Municipal Bond ETF
Occidental Asset Management LLC Has $2.09 Million Stock Position in iShares Russell 2000 Growth ETF
Occidental Asset Management LLC Has $2.09 Million Stock Position in iShares Russell 2000 Growth ETF
FirstCoin  Trading Down 14.5% Over Last Week
FirstCoin Trading Down 14.5% Over Last Week


© 2006-2019 Ticker Report